Diagonal Bio AB (publ) (NGM:DIABIO)
Sweden
· Delayed Price · Currency is SEK 0.0150
+0.0010 (7.14%)
At close: Apr 17, 2025
Diagonal Bio AB Revenue
In the year 2024, Diagonal Bio AB had annual revenue of 1.13M SEK, down -64.30%. Diagonal Bio AB had revenue of 343.00K in the quarter ending December 31, 2024, a decrease of -19.86%.
Revenue
1.13M
Revenue Growth
-64.30%
P/S Ratio
16.20
Revenue / Employee
225.00K
Employees
5
Market Cap
18.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.13M | -2.03M | -64.30% |
| Dec 31, 2023 | 3.15M | -555.00K | -14.98% |
| Dec 31, 2022 | 3.71M | -4.96M | -57.25% |
| Dec 31, 2021 | 8.67M | 672.67K | 8.41% |
| Dec 31, 2020 | 8.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.03B |
| Getinge AB | 34.76B |
| Sectra AB | 3.30B |
| Camurus AB | 1.87B |
| Medicover AB | 23.97B |
| Vitrolife AB | 3.61B |
| Bonesupport Holding AB | 898.73M |
| Vimian Group AB | 4.29B |